Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | PGK2 | P07205 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20724479 | 1.00 | ADORA3 (0.50) | ADORA3ADORA1ADORA2BNT5EADORA2A | |
| SCHEMBL20724586 | 0.92 | ADORA3 (0.51) | ADORA3ADORA1ADORA2BNT5EADORA2A | |
| SCHEMBL20724605 | 0.91 | P2RY1 (0.43) | ADORA3ADORA1ADORA2BNT5EADORA2A | |
| SCHEMBL20724477 | 0.91 | P2RY1 (0.43) | ADORA3ADORA1ADORA2BNT5EADORA2A | |
| SCHEMBL20724607 | 0.90 | NT5E (0.41) | ADORA3ADORA1ADORA2BNT5EADORA2A | |
| SCHEMBL19766012 | 0.88 | ADORA3 (0.56) | ADORA3ADORA1ADORA2BNT5EADORA2A | |
| SCHEMBL19766020 | 0.88 | ADORA3 (0.56) | ADORA3ADORA1ADORA2BNT5EADORA2A | |
| SCHEMBL20724608 | 0.86 | CYP2C19 (0.36) | ADORA3ADORA1NT5EADORA2A | |
| SCHEMBL19766083 | 0.82 | ADORA3 (0.57) | ADORA3ADORA1ADORA2BNT5EADORA2A | |
| SCHEMBL19766025 | 0.82 | ADORA3 (0.57) | ADORA3ADORA1ADORA2BNT5EADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202412-B2 | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections | Atea Pharmaceuticals, Inc. (US) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202412-B2 | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections | MTAP, NSUN2, PNP | ADORA3 89/4885ADORA1 106/4885ADORA2B 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.